A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation

CARACTERÍSTICAS DE LOS PACIENTES, PATRONES DE TRATAMIENTO Y RESULTADOS DE LOS PACIENTES CON CÁNCER DE PULMÓN NO MICROCÍTICO AVANZADO CON MUTACIONES DE INSERCIÓN EN EL EXÓN 20 DEL EGFR: REVISIÓN ETROSPECTIVA OBSERVACIONAL NO INTERVENCIONISTA DE HISTORIAS CLÍNICAS EN ESPAÑA. ESTUDIO ERMEX-20.

ENHANCE: A RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING MAGROLIMAB IN COMBINATION WITH AZACITIDINE VERSUS AZACITIDINE PLUS PLACEBO IN TREATMENT-NAÏVE PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME.

ESTUDIO FASE II, ALEATORIZADO, PARA EVALUAR LA INCIDENCIA DE DISCONTINUACIÓN DEBIDA A DIARREA EN LOS 3 PRIMEROS CICLOS DE TRATAMIENTO EN PACIENTES CON CÁNCER DE MAMA PRECOZ HER2 POSITIVO (HER2+), RECEPTOR HORMONAL POSITIVO (RH+), TRATADOS CON NERATINIB MÁS LOPERAMIDA VERSUS NERATINIB CON ESCALADA INICIAL DE DOSIS MÁS LOPERAMIDA (SEGÚN NECESIDAD) VERSUS NERATINIB MÁS LOPERAMIDA MÁS COLESEVELAM

A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis IPF

A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of CS1003 in Combination with Lenvatinib Compared to Placebo in Combination with Lenvatinib as First-Line Therapy in Subjects with Advanced Hepatocellular Carcinoma (HCC)

A Multicenter, Double-Blind, Randomized Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)

A multicenter, open label, randomized, Phase II trial to investigate soluble LAG-3 fusion protein, eftilagimod alpha (efti; IMP321) in combination with pembrolizumab (PD-1 antagonist) for first line treatment of subjects with unresectable recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined with Abiraterone Acetate and Prednisone (AA-P) versus Placebo Combined with AA-P as First-Line Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer

A multicenter, single-arm, open-label, extension, rollover study to evaluate. The long-term safety and efficacy of Ocrelizumab in patients with multiple Sclerosis

A multicentre, prospective, non-randomized, Phase I-II trial to assess the efficacy and safety of the combination of oral quizartinib and the FLAG-IDA chemotherapy regimen in first relapsed/refractory acute myeloid leukemia (R/R AML) patients

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors

A Phase 1b Study of ASP1948, Targeting an Immune Modulatory Receptor, as a Single Agent and in Combination with Nivolumab in Subjects with Advanced Solid Tumors

A Phase 2 Open-label Extension Study for Subjects with Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

A PHASE 2 STUDY OF CEMIPLIMAB, AN ANTI-PD-1 MONOCLONAL ANTIBODY, AND ISA101B VACCINE IN PATIENTS WITH RECURRENT/METASTATIC HPV16 CERVICAL CANCER WHO HAVE EXPERIENCED DISEASE PROGRESSION AFTER FIRST LINE CHEMOTHERAPY

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced Non–Small Cell Lung Cancer With an FGFR Alteration Who Progressed on Previous Therapy (FIGHT-210)

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209)

A Phase 2b,Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of PRV-015 in Adult Patients with Non-Responsive Celiac Disease as an Adjunct to a Gluten-free Diet

A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)

A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF NIVOLUMAB OR PLACEBO IN COMBINATION WITH DOCETAXEL, IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CHECKMATE 7DX:CHECKPOINT PATHWAY AND NIVOLUMAB CLINICAL TRIAL EVALUATION 7DX)